Acadia Pharmaceuticals | ACAD - Actif À Court Terme





Actif À Court Terme Changement Date
Acadia Pharmaceuticals USD 1.22B 128.53M 2026-06
ALKERMES USD 1.52B 164.26M 2026-06
Alnylam Pharmaceuticals USD 4.62B 400.86M 2026-06
Biogen USD 7.31B 1.88B 2026-06
BioMarin Pharmaceutical USD 3.97B 633.45M 2026-06
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Cara Therapeutics USD 25.33M 6.21M 2026-03
Corcept Therapeutics USD 439.68M 13.64M 2026-06
Cytokinetics USD 1.21B 369.02M 2026-06
Eisai JPY 883.01B 121.38B 2026-06
Eli Lilly USD 64.67B 9.84B 2026-06
Incyte USD 6.03B 542.31M 2026-06
J&J USD 59.77B 601M 2026-06
Moderna USD 5.82B 45M 2026-06
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Pfizer USD 41.36B 1.46B 2026-06
Prothena USD 292.01M 47.19M 2026-06
PTC Therapeutics USD 2.62B 363.36M 2026-06
Sarepta Therapeutics USD 2.22B 86.05M 2026-06
Ultragenyx Pharmaceutical USD 606M 51M 2026-06
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Vertex Pharmaceuticals USD 12.54B 813.4M 2026-06